Abstract ALK1 (ACVRL1) is a member of the TGFb receptor family and is expressed predominantly by arterial endothelial cells (EC). Mutations in ACVRL1 are responsible for hereditary hemorrhagic telangiectasia type 2 (HHT2), a disease manifesting as fragile vessels, capillary overgrowth, and numerous arterio-venous malformations. Arterial EC also express EphrinB2, which has multiple roles in vascular development and angiogenesis and is known to be reduced in ACVRL1 knockout mice. Using an in vitro angiogenesis model we find that the Alk1 ligand BMP9 induces EphrinB2 in EC, and this is entirely dependent on expression of Alk1 and at least one of the coreceptors BMPRII or ActRII. BMP9 induces both ID1 and ID3, and both are necessary for full induction of EphrinB2. Loss of Alk1 or EphrinB2 results in increased arterialvenous anastomosis, while loss of Alk1 but not EphrinB2 results in increased VEGFR2 expression and enhanced capillary sprouting. Conversely, BMP9 blocks EC sprouting and this is dependent on Alk1, BMPRII/ActRII and ID1/ID3. Finally, notch signaling overcomes the loss of Alk1-restoring EphrinB2 expression in EC, and curbing excess sprouting. Thus, in an in vitro model of HHT2, loss of Alk1 blocks BMP9 signaling, resulting in reduced EphrinB2 expression, enhanced VEGFR2 expression, and misregulated EC sprouting and anastomosis.
Introduction
Hereditary hemorrhagic telangiectasia (HHT) represents a spectrum of diseases characterized by fragile telangiectatic vessels in numerous mucosal tissues, and arteriovenous malformations (AVMs), predominantly in lungs, liver, gastrointestinal tract, and brain. These defects manifest as recurrent nosebleeds (epistaxis), and in severe cases, ischemic injuries or stroke. HHT occurs with a frequency of approximately 1:5,000 individuals [1] , with some regional differences [2] , and is inherited as an autosomal dominant trait [3] . HHT1 and HHT2 are caused by mutations in the endoglin (ENG) and Alk1 (ACVRL1) genes, respectively [4, 5] , each of which are involved in TGFb-family signaling [6, 7] .
Although the genetic underpinnings of HHT are known, the specific cellular and molecular mechanisms are not well understood, especially why only some vascular beds are affected, and what the relevant ligands are for these receptors. Recent work in a mouse model for HHT2 has provided compelling evidence that environmental factors such as wounds, in addition to mutation or loss of Alk1, are required for the formation of AVMs in adult mice [8] , however there is still much to be learned about the molecular role of Alk1 in vascular homeostasis and/or angiogenesis. In addition there is mounting evidence for involvement of modifier genes, although these are much less well characterized [9, 10] .
Alk1 is one of seven type I receptors for the TGFb family of signaling molecules, and is expressed predominantly by endothelial cells (EC) where it is largely restricted to the arterial side of the vasculature, except during angiogenesis, where it is also expressed on activated EC [11] . Alk1, a serine/threonine kinase, has been shown to bind TGFb1 as well as activins and recent work has also identified it as a receptor for BMP9 and BMP10 [12] [13] [14] [15] [16] . Type I receptors bind ligand in conjunction with type II receptors, also serine/threonine kinases, which triggers phosphorylation of the smad signaling intermediates, which in the case of Alk1 are smad1, 5, and 8. Interestingly, other TGFb receptors, such as Alk5, signal through smad2 and smad3 [15, 17] . Type II receptors expressed by EC include TGFbRII, BMPRII and ActRII. EC also express a type III receptor, ENG, mutations in which are responsible for HHT1 [5, 15, 17] . ENG is expressed on both sides of the vascular tree and it is thought to potentiate binding of ligand to the type I and II receptors.
The effect of TGFb signaling on EC in culture appears to depend on a number of factors, including, concentration, duration of signaling, the type of EC used and possibly their length of time in culture [15] . Generally, TGFb is thought to block proliferation and migration and to induce matrix proteins such as fibronectin and collagens I, IV and V. Defining the downstream targets and effects of Alk1 has been even more perplexing, particularly because of the conflicting data on the expression and role of Alk5 in EC [18, 19] . Several groups have used constitutively active (CA) forms of these receptors, but have rarely reported congruent results [20] [21] [22] [23] [24] . For example, Ota et al. [24] found that both Alk1 and Alk5 blocked proliferation of HUVEC, but only CA-Alk5 blocked tube formation in collagen gels. Goumans et al. [20] on the other hand, found that CA-Alk1 increased migration of mouse embryonic endothelial cells, whereas CA-Alk5 decreased migration. Others have reported that both CA-Alk1 and CA-Alk5 block vascular sprouting from embryoid bodies [23] . A model has been proposed to reconcile these disparate results based on the idea of Alk1 and Alk5 balancing responses to TGFb family ligands in response to different ligand concentrations [25, 26] . This balance hypothesis is, however, challenged by studies in zebrafish-where the loss of Alk1 (violet beauregarde) results in increased numbers of EC, suggesting that Alk1 normally acts to block EC proliferation [27] ; and in micewhere a lacZ knock-in indicated that, at least during early development, Alk5 is not expressed by EC but is restricted to the vessel media, especially smooth muscle cells [19] . Thus, on balance, it appears likely that Alk1 acts to suppress EC migration and possibly proliferation, thereby helping to maintain them in a quiescent state. Several recent in vitro studies also support this interpretation [14, 21, 23, 28] .
The idea that TGFb is the predominant ligand for Alk1 has been challenged in a number of studies. For example, whereas vascular-specific targeting of Alk1 recapitulates the phenotype of HHT2 [29] , vascular-specific targeting of TGFbRII, which is the major type II receptor for TGFb on EC, has no vascular phenotype [18] . Similarly, vascular targeting of Alk5, also has no effect on blood vessel development [18] . Consistent with these findings, BMP9 and BMP10 have been identified as two high-affinity ligands for Alk1 [13, 14, 16] and the BMP receptor, BMPRII, is expressed by EC. BMP9 is present in human serum at around 2-12 ng/ml (40-250 pM), which is several-fold higher than the Kd for the receptor (reported to be around 1 pM) suggesting that Alk1 may be tonically activated to maintain vascular quiescence [13] . BMP9 stimulation of EC has been shown to induce a number of genes, including ID1, and to inhibit EC proliferation of pulmonary EC [30] .
Previous studies of Alk1 knockout mice noted loss of EphrinB2 expression by EC [29] . EphrinB2 and its ligand EphB4 define arteries and veins respectively, and are thought to have a role in preventing direct arterio-venous anastomoses [31, 32] . Interestingly, although notch1 and notch4 are also essential for maintaining vessel identity, Alk1 mutants show strong similarities to notch gain-offunction mutants [33] . Recently, several reports have suggested that EphrinB2 also has functions aside from maintaining vessel identity, including roles in EC morphology and motility [34, 35] , possibly downstream of effects on VEGF receptor internalization and signaling [36, 37] .
We have investigated the relationship between BMP9, Alk1 and EphrinB2 in an in vitro angiogenesis model of HHT2 and find that BMP9 induces EphrinB2 expression through an Alk1-ID1/3 pathway. Moreover, loss of Alk1 in EC (mimicking HHT2) results in a loss of BMP9-induced EphrinB2, up regulation of VEGFR2 expression, and misregulated vascular sprouting and anastomosis. Finally, the loss of EphrinB2 expression in Alk1 knock-out EC can be overcome by enhanced notch signaling.
Materials and methods

Cell culture and other reagents
Human Umbilical Vein Endothelial Cells (HUVEC) and Endothelial Colony-forming Cell derived EC (ECFC-EC) cell lines were isolated from umbilical cords obtained from local hospitals under University of California, Irvine Institutional Review Board approval. Human Umbilical Artery Endothelial Cells (HUAEC) were purchased from Lonza (Allendale, NJ). BMP9 and antibody for EphrinB2 and b-actin were from R&D systems (Minneapolis, MN), Santa Cruz Biotechnology Inc (Santa Cruz, CA), and Abcam (Cambridge, MA). The siRNA for control, ALK1, ID1, ID3, ActRII, BMPRII and EphrinB2 were purchased from Ambion (Austin, TX). The ALK1 expression constructs were generous gifts from Dr. Paul Oh (U. Florida). Where used, BMP9 was added in serum-free medium.
Fibrin gel sprouting assay
The 3D in vitro fibrin gel sprouting assay model of angiogenesis was performed as described previously [38] . Briefly, primary HUVEC, HUAEC or ECFC-EC (200 cells/bead)-coated Cytodex3 beads (Sigma-Aldrich Co., St. Louis, MO) in fibrin gels were cultured in 24 well plates (250 beads/well) in EGM2 medium with normal human lung fibroblasts (NHLF, 20,000 cells/well) plated on top of the gel. After 6-8 days the beads were photographed using an Olympus IX70 inverted phase contrast/fluorescence microscope (Melville, NY), and the sprouts whose lengths were greater than the diameter of the bead were counted. Lumen formation was quantified by counting the number of sprouts that had formed lumens and results are expressed as a percentage. Counts were performed blinded to the treatment group. To investigate anastomosis using HUVEC and HUAEC, we generated retrovirus stocks using packaging plasmid pBMN-GFP and mCherry with Phoenix retrovirus packaging system from Orbigen, and transduced the HUVEC and HUAEC with GFP and mCherry, respectively. After transfection of siRNA for control, EphrinB2, EphB4 and ALK1, beads coated with HUVEC or HUAEC were mixed and cultured in fibrin gels with human lung fibroblasts on top of the gel. The sprouts that formed connections between HUVEC-and HUAEC-coated beads were counted.
Transfection of plasmids and siRNAs HUVEC, HUAEC and ECFC-EC (1.5 9 10 6 cells/100-mm dish) cells were seeded and transfected with either pDelta4 (5 lg), pcDNA 3.1 (5 lg) or siRNA (13 pmol/6 well plate) using the Lipofectamine 2000 reagent (Life Technologies).
For the luciferase reporter assay, luciferase constructs (0.5 lg) were cotransfected into EC. The cells were transfected in serum-free medium for 3 h and then were switched to a medium containing 10 % FBS. Cells were then incorporated into the fibrin gel sprouting assay, luciferase reporter assays, western blot analysis or qRT-PCR analysis. For western blot analyses, whole-cell lysates were prepared after transfection of siRNA for control and ALK1. For luciferase activity, cell extracts were assayed using luciferin (Sigma-Aldrich) as the substrate and normalized to protein concentration. Luciferase activities were expressed as the mean ± SD of measurements made from three identical wells.
Quantitative RT-PCR Quantitative Real Time-PCR was performed as described previously [39] . Briefly, RNA isolation and cDNA synthesis were performed using the Trizol (Qiagen) and the iScript cDNA Synthesis kit (Bio-Rad, Madison, WI). The cDNA was synthesized from 1 lg of total RNA in a 25-ll volume. The reaction was incubated at 25°C for 5 min and at 37°C for 30 min and then inactivated at 85°C for 5 min. Real time PCR analysis was performed on an IQ5 real time PCR (Bio-Rad) using the following primers: For EphrinB2 (GenBank accession number, NM_004093), luciferase reporter vector pGL3-Basic (Promega). The DNA sequence of the EphrinB2 promoter was confirmed by DNA sequencing.
Microscopy
Visualization of fibrin gel sprouting assays was performed using brightfield images collected on an inverted microscope (Olympus IX70) with a SPOT Idea 3.0 megapixel color mosaic camera and SPOT software (SPOT Imaging Solutions, Sterling Heights MI). For confocal images, cells were stained with DAPI and Texas Red-X phalloidin (Invitrogen, St. Louis, MO). Confocal images were collected using an Olympus Fluorview FV1000 confocal microscope. Images were processed in Adobe Photoshop (Adobe Systems Inc., San Jose, CA) to adjust contrast and color balance. All images in a given experiment were treated similarly.
Statistical analysis
Data are shown as the mean ± SEM. For statistical significance between groups, we used a paired Student t test with p values \ 0.05 being considered significant.
Results
For these studies we used three types of endothelial cells (EC) to investigate the Alk1-EphrinB2 pathway-human umbilical vein EC (HUVEC), human umbilical artery EC (HUAEC) and cord blood endothelial colony-forming cellderived EC (ECFC-EC). As expected, HUAEC expressed high levels of EphrinB2 and low levels of the vein markers EphB4 and COUPTFII (Fig. S1 ). HUVEC expressed EphB4, COUPTFII, and moderate levels of EphrinB2. ECFC-EC had what appeared to be a non-committed phenotype, expressing EphrinB2 at levels comparable to HUAEC, and EphB4 and COUPTFII at levels comparable to HUVEC (Fig. S1 ).
BMP9 induces EphrinB2 through Alk1, BMPR-II and ActR-II
To confirm in human cells the previous finding in mice that cells lacking Alk1 have decreased expression of EphrinB2 we treated HUAEC with siRNA to Alk1. We confirmed successful and specific knockdown of the target mRNA, consistently finding greater than 80 % reduction in the specific target, with no effect on the untargeted gene (Fig. 1a) . Loss of Alk1 reduced EphrinB2 expression by close to 80 % (Fig. 1a) consistent with previous work showing that a constitutively active Alk1 increased EphrinB2 expression in EC [24] . A second siRNA directed to Alk1 also reduced EphrinB2 expression, thereby excluding off-target effects as an explanation for this result (data not shown). EphrinB2 protein levels were also reduced by knockdown of Alk1 as demonstrated by Western blotting (Fig. 1a) . BMP9 has been identified as a ligand for Alk1, and so we tested whether BMP9 can induce EphrinB2. As shown in Fig. 1b , this is indeed the case, and moreover, the activity of BMP9 is entirely dependent on the expression of Alk1 (Fig. 1b) . A constitutively active (CA) form of Alk1, conversely, strongly induced EphrinB2 expression (Fig. 1c) . As a further test of the ability of BMP9 to induce EphrinB2 expression we cloned 1.1 kb of the EphrinB2 proximal promoter upstream of luciferase and transfected this construct into EC. BMP9 strongly induced luciferase expression (Fig. 1d) . BMP9 is present in serum at concentrations of 2-12 ng/ml [13] and we confirmed that increasing doses of serum also induced the EphrinB2 promoter (Fig. 1d) . In addition to signaling through the type I receptor Alk1, BMP9 has also been reported to require the two type II receptors, BMPR-II and ActR-II [30] and we confirmed that finding here-loss of both type II receptors completely blocked BMP9 induction of EphrinB2 (Fig. 1e) , whereas loss of either alone had no effect (data not shown). Thus, BMP9 induces EphrinB2 expression in EC through a combination of Alk1, and BMPR-II or ActR-II receptor signaling.
BMP9 induction of EphrinB2 depends on ID1 and ID3
Previous studies have shown that BMP9 and Alk1 induce expression of the transcription factors ID1 and ID3 [20, 22, 24, 28] . Moreover, mice deficient in both ID1 and ID3 have severely compromised physiologic and pathologic angiogenesis [40] . We confirmed that both ID1 and ID3 are dose-dependently induced by BMP9 in HUVEC (data not shown) and in HUAEC (Fig. 2a) . To determine whether ID1 and ID3 mediate BMP9/Alk1 induction of EphrinB2 we transfected HUAEC with control siRNA or siRNA to ID1 or ID3 and then stimulated them with BMP9. Knockdown of ID1 and ID3 was confirmed by qRT-PCR. Loss of either ID1 or ID3 singly reduced BMP9-induced EphrinB2 expression by about 50 %, whereas knockdown of both ID1 and ID3 reduced induction by up to 90 % (Fig. 2b) . Conversely, overexpression of ID1 induced EphrinB2 (data not shown). Thus, EphrinB2 expression is transcriptionally upregulated in EC through a BMP9-Alk1-BMPR-II/ActR-II-ID1/3 pathway.
Notch signaling rescues EphrinB2 expression in Alk1 knockdown cells
It has been noted that in mice lacking Alk1, or overexpressing activated notch, similar arteriovenous malformations (AVMs) are formed-in one case loss of Alk1 results in arteries taking on a venular phenotype (EphrinB2-), while in the other, notch activation drives veins toward an arterial phenotype (EphrinB2?) [33] . We wondered, therefore, whether activation of the notch pathway in EC could rescue EphrinB2 expression in cells lacking Alk1. To this end we transfected EC with control siRNA or siRNA to Alk1, and then mixed these with cells transfected with an expression plasmid for the notch ligand dll4. In cells receiving control siRNA dll4 stimulated a robust 2 to threefold increase in EphrinB2 expression (Fig. 2c) .
As before, siRNA-Alk1 reduced EphrinB2 expression. Remarkably, dll4-mediated notch signaling was able to completely overcome the effect of Alk1 knockdown and restore EphrinB2 expression (Fig. 2c) . Efficient Alk1 knockdown was confirmed as was dll4 induction of the well-characterized notch target HES-1 (Fig. 2d) . Thus, our data show that loss of Alk1 signaling to EphrinB2 can be overcome by enhanced dll4-mediated notch signaling.
Loss of Alk1 increases endothelial sprouting
To determine the role of Alk1 on endothelial sprouting we used an in vitro assay that recapitulates several of the necessary steps of angiogenesis, including sprouting, migration, alignment, proliferation, and tube formation [38] . HUAEC were transfected with either control siRNA or siRNA specific to Alk1, allowed to attach to beads and then plated into fibrin gels. Knockdown of Alk1 resulted in a significant 2-3-fold increase in both the number of sprouts and the number of tip cells-an indicator of branching (Fig. 3a, d ). Sprouts that form in this assay invariably remain attached at their base to the bead and single migrating cells are rarely seen. In contrast to this we noted a significant increase in single cells migrating away from the bead when Alk1 expression was reduced, (Fig. 3b, d ). HUVEC, unlike most vein-derived EC also express Alk1 although to lesser levels than arterial cells (data not shown). HUVEC also showed enhanced sprouting when Alk1 expression was knocked down (Fig. 3e, h ) and similar to HUAEC, loss of Alk1, led to a significant number of single EC migrating away from the beads (Fig. 3f, h) . Finally, we also tested EC derived from cord blood endothelial cell colony-forming cells (ECFC-EC), which have a phenotype reflecting characteristics of both HUAEC and HUVEC (Fig. S1 ). These also showed enhanced sprouting in response to loss of Alk1 (Fig. 3i, l) , as well as dramatically increased migration of single cells (Fig. 3j, l) . In all cases we confirmed specific and efficient knockdown of the target gene (Fig. 3c, g, k) . Thus in three different EC lineages loss of Alk1 results in enhanced sprouting and the appearance of single migrating cells.
To determine whether the increased sprouting was due to an increase in cell proliferation we cultured siRNAtreated HUAEC at low, medium or high density and measured cell number by MTT assay after three days of culture. As shown in Fig. 4a , loss of Alk1 had no effect on EC proliferation, suggesting that the increased number of sprouts is not merely due to an increase in cell number.
As further confirmation of the role of Alk1 in regulating sprouting we transfected EC with expression plasmids encoding a constitutively active form of Alk1 (CA-Alk1) or, as a positive control, constitutively active notch (NICD), and examined these cells in a sprouting assay. As predicted, both constructs significantly suppressed sprouting compared to a GFP control (Fig. 4b) , consistent with the loss of Alk1, or the suppression of notch signaling inducing augmented sprouting [ Fig. 3; (41) ]. Given that both Alk1 signaling and notch signaling suppress sprouting we wondered whether inhibition of notch signaling would relieve the suppressive effects of Alk1. We therefore transfected EC with control or Alk1 expression plasmids and treated the cells with vehicle or the notch inhibitor DAPT. Loss of notch signaling did not relieve inhibition by Alk1 (Fig. S2A) . In a reverse experiment, we looked at whether loss of Alk1 would reverse the suppressive effect of notch signaling on sprouting. Cells were transfected with control or Alk1 siRNA and with control or dll4 expression plasmids. Dll4-mediated notch signaling strongly suppressed sprouting even in the absence of Alk1 (Fig. S2B) . Therefore, inhibition of sprouting by Alk1 signaling is not relieved by loss of notch, nor is inhibition by notch signaling Fig. 2 relieved by loss of Alk1, suggesting that the two pathways act to suppress sprouting largely independently of each other, although they may have some redundant overlap (see below).
Under some culture conditions sprouting occurs normally and yet the neovessels fail to form lumens [42] . We examined sprouts formed by control, or Alk1 or EphrinB2 knockdown EC by phase contrast (Fig. 4c-e) and confocal (Fig. 4f, g ) microscopy for evidence of lumen formation. Neither loss of Alk1 or EphrinB2 compromised the ability of vessels to undergo lumen formation. We conclude, therefore, that Alk1 and EphrinB2 are not involved in lumenogenesis. Our previous work similarly ruled out a role for notch in this process [41] .
In summary, Alk1 signaling normally acts to suppress EC sprouting. The loss of Alk1 results in enhanced sprouting, and this can be reversed by notch signaling.
BMP9 acts through Alk1 to block EC sprouting
It has been shown that BMP9 blocks EC migration [13, 43] , and our data show that siRNA to Alk1 enhances EC sprouting, while CA-Alk1 blocks sprouting, suggesting that BMP9 should block sprouting. To test this directly we added BMP9 to EC embedded in fibrin gels and then counted the number of sprouts. Confirming our findings with siRNA to Alk1 and CA-Alk1, BMP9 dose-dependently blocked sprout formation in both HUAEC (Fig. 5a ) and in HUVEC (Fig. 5b) . Pretreatment of the EC with siRNA to Alk1 blocked the ability of BMP9 to suppress sprouting, again confirming the necessity of Alk1 for BMP9 effects on EC. Similarly, knockdown of ID1/ID3 also blocked the ability of BMP9 to inhibit sprouting (data not shown). Our data suggest therefore that BMP9 acts through Alk1 to suppress EC sprouting. As shown above using CA-Alk1 and NICD (Fig. S2) , each pathway appears to act largely independently to suppress sprouting. We confirmed that finding using BMP9 in place of CA-Alk1. As shown in Fig. S3 , inhibition of sprouting by BMP9 (as measured by the number of tip cells) could not be overcome by concomitant loss of notch signaling in the presence of DAPT.
As EphrinB2 is implicated in maintenance of vessel identity [44] and both EphrinB2 and Alk1 knockout mice display AVMs [29, 33] we tested whether loss of Alk1 or EphrinB2 would alter artery-vein anastomosis in vitro. Sprouting assays were established containing mCherryexpressing HUAEC and GFP-expressing HUVEC, treated with either control, Alk1, EphrinB2 or EphB4 siRNAs. Interbead anastomoses were then counted under fluorescent illumination. As shown in Fig. 5c , loss of Alk1 in HUAEC led to a significant increase in anastomosis with control HUVEC. Direct knockdown of EphrinB2 similarly increased anastomosis. In both cases, simultaneous loss of the EphrinB2 receptor EphB4 in the HUVEC potentiated the increase, although not to a statistically significant level. A-V connections were still relatively rare, however-approximately tenfold less frequent than either A-A or V-V connections, the rate of which was not altered (data not shown). Thus, loss of Alk1 in arterial EC mirrors the loss of EphrinB2 in promoting anastomosis between arterial and venular EC.
Loss of Alk1 or EphrinB2 suppresses induction of a VEGF-target gene
Sprouting angiogenesis is strongly dependent on VEGF signaling through VEGFR2, the expression of which is enriched in tip cells [45] . We looked, therefore, at whether loss of Alk1 affected VEGFR2 expression. As shown in Fig. 6a , treatment of EC with siAlk1 strongly induced VEGFR2 expression, whereas loss of EphrinB2 had no effect. Our previous work has shown that notch signaling induces expression of the bHLH transcription factor HESR1 (HEY1) and that this down regulates VEGFR2 transcription [46] [47] [48] . Here we find that BMP9 also induces HESR1 expression (Fig. 6b) , providing a molecular link between loss of Alk1 and up regulated VEGFR2. Finally, we tested whether increased VEGFR2 expression in response to loss of Alk1 correlated with a change in the level of sprouting at different concentrations of VEGF, and indeed it did. We saw a dramatic increase in responsiveness, especially at higher concentrations of VEGF (Fig. 6c ).
Discussion
Our findings provide further evidence that Alk1 is a critical type I receptor for BMP9 on human EC, although a role for Alk5 (or other Alk receptors) has not been ruled out. We find that BMP9 signaling through Alk1, in combination with BMPRII or ActRII, up regulates ID1 and ID3, which in turn cooperate to induce EphrinB2 expression. Loss of Alk1, results in enhanced EC sprouting, and this correlates with enhanced responsiveness of EC to VEGF. We now provide a mechanistic link between Alk1 and EphrinB2, through ID1 and ID3, and also demonstrate that the loss of EphrinB2 expression downstream of defective Alk1 can be rescued by dll4-mediated notch signaling (Summarized in Fig. 7) . A recent study [33] noted the surprising finding that although notch signaling induces EphrinB2 expression, the phenotype associated with loss of EphrinB2 was mirrored best not by a notch loss-of-function (LOF) mutant but by a notch gain-of-function (GOF) mouse. These data imply that the phenotypes in the EphrinB2 LOF mice and the notch GOF mice arise by different mechanisms-potentially, a conversion of artery to vein in the former and conversion of vein to artery in the latter. Our data showing that notch activation downstream of over-expressed dll4 rescues EphrinB2 expression in EC (Fig. 2) suggest, therefore, that spatially-restricted activation of notch-in the arterial side of the vasculature only-might limit the formation of AVMs in an Alk1 mutant background (HHT2). Unrestricted expression, however, that included the venous side of the circulation, might also trigger AVMs as has previously been shown by induced expression of notch ICD in adult mice [49] . These data raise the possibility that components of the notch pathway may act as modifier genes in HHT [15, [50] [51] [52] . Such modifier genes have been suggested as an explanation for strain differences in the penetrance of the HHT1 phenotype in Endoglin haploinsufficient mice [10, 53, 54] . Our results on the role of BMP9 in inducing ID protein expression are consistent with the recent findings of Upton et al. [30] , who used pulmonary arterial EC. In that study BMP9 was found to induce both ID1 and ID2, through a pathway dependent on Alk1 and BMPRII or ActRII. In human umbilical artery EC we find that BMP9 induces ID1 and ID3 (and ID2, data not shown), and that similarly to the findings of Upton et al. [30] the two type II receptors act redundantly-only loss of both receptors blocked BMP9 induction of EphrinB2 (Fig. 1d) . This is consistent with mouse studies showing that loss of TGFbRII in EC does not result in a vascular defect [18] .
The effect of ID1/ID3 on EphrinB2 promoter activity is likely to be indirect as ID proteins usually act as negative regulators of transcription through their binding to E-boxes. BMP9-regulated Smads, however, may have direct effects as we identified numerous BMP-response elements [55] in the EphrinB2 proximal promoter (Fig.  S4) , at least some of which are conserved across multiple species (Fig. S5) . The VEGFR2 promoter does, however, have numerous E-boxes [47] and may therefore be a direct target of negative regulation by ID1/ID3 (Fig. 7a) .
A recent study in zebrafish reported that loss of Alk1 resulted in an increase in endothelial cell numbers in arteries, and that the formation of AVMs was a result of aberrant retention of venous-derived conduits [27, 56] . A Fig. 6 Alk1 regulates VEGFR2 expression a HUAEC were transfected with control siRNA or siRNA to Alk1 or EphrinB2 and cultured for 2 days. Expression of the VEGF receptor VEGFR2 was then assessed by qRT-PCR. b HUAEC were treated for 18 h with 1 ng/ml BMP9 and HESR1 expression was assessed by qRT-PCR. c HUAEC were transfected with control siRNA or siRNA to Alk1, established in an in vitro angiogenesis assay, and cultured with VEGF at the indicated concentrations. Sprouts were counted after 8 days. All data are shown as mean and SEM. p Values are for Student t tests. * p \ 0.05; ** p \ 0.01 Fig. 7 Summary of EphrinB2 and VEGFR2 regulation a Schematic of BMP9 signaling in EC. BMP9, acting through Alk1/ActRII/ BMPRII, targets ID1 and ID3, which then up regulate the EphrinB2 promoter, presumably indirectly. Smad1/5/8 downstream of Alk1 may regulate the EphrinB2 promoter directly as it contains numerous BMP response elements (see Fig. S4, S5 ). Notch signaling also upregulates EphrinB2, through a 5' RBPj binding site. Alk1 signaling down-regulates VEGFR2 mRNA, and this may be through direct binding of ID1/ID3 to the E-boxes in the VEGFR2 promoter region or by its induction of HESR1. EphrinB2 and VEGFR2 may interact at the cell surface to further modulate VEGF signaling. b Alk1 balances EphrinB2 and VEGFR2 expression. Loss of Alk1 in EC results in decreased EphrinB2 expression but increased VEGFR2 expression. Loss of Alk1, and increased VEGFR2 expression, correlates with enhanced sprouting possible role for enhanced EC proliferation was not confirmed, however other studies have noted decreased EC proliferation in response to BMP9 or CA-Alk1 [13, 21, 28] . Although it appears that the initial increase in vessel caliber in Alk1 mutants is independent of flow, the later dilation of arteries, and subsequently of draining veins, is flowdependent [56] . An elegant study in mice, using a dorsal skin-fold model, reported similar findings-early A-V anastomoses preceding dilatation of postcapillary venules and remodeling of arterial vessels [8] . We also see enhanced anastomosis between artery and vein EC when Alk1 expression is reduced and this is phenocopied by loss of either EphrinB2 or EphB4 (Fig. 5c ). BMP9 has also been reported to induce EC proliferation in vitro [57] , however we were not able to reproduce those findings here. Indeed, our findings almost completely mirror those of Suzuki in that we see BMP9-mediated-inhibition of EC sprouting, and in the absence of Alk1 we see an increase in VEGFR2, rather than a decrease. These discrepancies may relate to species differences as all of our studies were done with human cells whereas Suzuki et al. used mouse. A resolution to this will likely require head-to-head comparative studies.
Our data suggest that loss of Alk1 signaling has multiple consequences: these include not only the loss of EphrinB2 expression discussed above, but also the loss of proper regulation of VEGFR2. The interactions between Alk1 and notch signaling are complex. Down regulation of EphrinB2 as a consequence of Alk1 loss can be overcome by activating notch (Fig. 2c) , indicating that notch can regulate EphrinB2 transcription independently of Alk1. Similarly, activated notch can suppress sprouting regardless of whether Alk1 signaling is active (Fig. S2) . Both notch and BMP9 can induce HESR1 expression, and both can down regulate VEGFR2. In HHT2, therefore, the loss of Alk1-mediated BMP9 signaling could drive angiogenesis and vascular overgrowth through up regulation of VEGFR2 transcription in the absence of HESR1-mediated suppression (Fig. 7a) . A prediction from this model would be that increasing notch signaling on an Alk1 knockdown background should suppress the excess sprouting by restoring HESR1 expression, and indeed, this is the case-dll4-mediated notch signaling is dominant over loss of Alk1 in regulation of sprouting (Fig. S2B) . Similarly, enhanced sprouting as a consequence of notch inhibition is overcome by the addition of BMP9 (Fig. S3) .
Intriguingly, recent reports have shown efficacy of bevacizumab, an anti-VEGF antibody, in treating epistaxis in HHT patients [58] . It is likely that the antibody blocks the angiogenesis phase of the perpetual cycle that is the hallmark of HHT patients suffering continual nose bleeding: damage to fragile vessels-bleeding-tissue damageangiogenesis-vessel damage, etc. Clearly, regulation of VEGF signaling in HHT is critical.
Taken together, our data along with previously-published studies, suggest an underlying mechanism for the formation of telangiectasias and AVMs that involves altered VEGF signaling downstream of mutant Alk1, as a consequence of up regulated VEGFR2 expression, combined with reduced EphrinB2 expression. The outcome is enhanced sprouting, but misregulated anastomosis (Fig. 7b) . Finally, it is possible that local enhancement of notch signaling may have some beneficial effects in HHT.
